Pharma Journalist -

Pfizer and Astellas Pharma announced that a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) has been accepted for filing and granted Priority Review designation by…
Read More...

Ionis Pharmaceuticals and Akcea Therapeutics, Inc., an affiliate of Ionis, announced an exclusive, worldwide license by Ionis to Akcea for inotersen and AKCEA-TTR-LRx, formerly…
Read More...

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement,…
Read More...

Intezyne announced that it has partnered with Exosome Diagnostics, a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics, to design…
Read More...

Mallinckrodt plc announced it has closed the sale of RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant to Baxter International Inc. "This action further…
Read More...

Ardelyx, Inc. announced a license agreement with Knight Therapeutics, Inc. (Knight) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is…
Read More...

Nexcelom Bioscience announced that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom's worldwide growth…
Read More...

Global pharmaceutical company Mylan N.V. announced the U.S. launch of the oncology drug Mitomycin for Injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial Single Dose Vials, a generic…
Read More...

Akcea Therapeutics United Kingdom (UK) Ltd announced that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the UK’s…
Read More...

Kalytera Therapeutics announced that it has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been…
Read More...